- Home
- CVR vs BTAI Comparison
CVR vs BTAI Comparison
Compare CVR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- BTAI
- Stock Information
- Founded
- CVR 1920
- BTAI 2017
- Country
- CVR United States
- BTAI United States
- Employees
- CVR 207
- BTAI N/A
- Industry
- CVR Industrial Machinery/Components
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CVR Industrials
- BTAI Health Care
- Exchange
- CVR Nasdaq
- BTAI Nasdaq
- Market Cap
- CVR 14.9M
- BTAI 18.1M
- IPO Year
- CVR N/A
- BTAI 2018
- Fundamental
- Price
- CVR $15.43
- BTAI $0.37
- Analyst Decision
- CVR
- BTAI Buy
- Analyst Count
- CVR 0
- BTAI 4
- Target Price
- CVR N/A
- BTAI $2.81
- AVG Volume (30 Days)
- CVR 1.2K
- BTAI 1.3M
- Earning Date
- CVR 11-12-2024
- BTAI 03-11-2025
- Dividend Yield
- CVR 2.13%
- BTAI N/A
- EPS Growth
- CVR N/A
- BTAI N/A
- EPS
- CVR N/A
- BTAI N/A
- Revenue
- CVR $29,663,473.00
- BTAI $2,276,000.00
- Revenue This Year
- CVR N/A
- BTAI $131.45
- Revenue Next Year
- CVR N/A
- BTAI $45.65
- P/E Ratio
- CVR N/A
- BTAI N/A
- Revenue Growth
- CVR N/A
- BTAI 83.25
- 52 Week Low
- CVR $13.81
- BTAI $0.30
- 52 Week High
- CVR $22.27
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- CVR 40.66
- BTAI 51.15
- Support Level
- CVR $15.55
- BTAI $0.33
- Resistance Level
- CVR $15.94
- BTAI $0.39
- Average True Range (ATR)
- CVR 0.23
- BTAI 0.06
- MACD
- CVR 0.04
- BTAI 0.00
- Stochastic Oscillator
- CVR 7.07
- BTAI 34.59
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment. Geographically, the majority is from the United States.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.